Our new review on the evidence for primary prevention aspirin in individuals with elevated Lp(a) is out now. #CardioSky

@ucsdcardiology.bsky.social @aspcardio.bsky.social @familyheartfdn.bsky.social

link.springer.com/epdf/10.1007...

Enjoyed presenting our work on Lp(a) and the PREVENT equations #AHA25 #CardioSky @ucsdcardiology.bsky.social

Dr. Andrew Kao presenting work on Lp(a) and ischemic stroke #ACC25
@ucsdcardiology.bsky.social

Kavenpreet Bal presenting work on Lp(a) in South Asian individuals #ACC25 @ucsdcardiology.bsky.social

I am excited to be speaking at the 5th Annual Going Back to the Heart of Cardiology Conference January 24-26 in Miami Beach. Looking forward to sharing and learning alongside the best in the field. See you there! Register here: heartofcardio.com
#HeartofCardio #Cardiosky

In our new study in EJPC, optimal CVD risk factor control was a/w lower risk across Lp(a) levels, though residual risk remains. These results show the importance of aggressive risk factor mgmt in patients with elevated Lp(a). @alexrazavi.bsky.social

academic.oup.com/eurjpc/advan...